Prognostic value of a cell cycle progression score for men with prostate cancer

Recent Results in Cancer Research

Volumn 202, Issue , 2014, Pages 133-140

  Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL CYCLE PROGRESSION GENE; CLINICAL FEATURE; GENE FUNCTION; GENE IDENTIFICATION; GLEASON SCORE; HUMAN; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; ANTIGEN DETECTION; CANCER RECURRENCE; CELL CYCLE PROGRESSION SCORE; COHORT ANALYSIS; DISEASE SURVEILLANCE; EXTERNAL BEAM RADIOTHERAPY; GENE; HOUSEKEEPING GENE; NEEDLE BIOPSY; PREDICTIVE VALUE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

CELL CYCLE PROTEINS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS;

EID: 84958539988     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-45195-9_16     Document Type: Article

References (16)

1. Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Reuter V, Eastham J, Moller H, Kattan MW, Gerald W, Cooper C, Scardino P, Cuzick J (2009) Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic prostate group study. Br J Cancer 100(6): 888-893
2. Chao C, Chi M, Preciado M, Black MH (2013) Methylation markers for prostate cancer prognosis: a systematic review. Cancer Causes Control. Jun 25 [Epub ahead of print]
3. Cooperberg MR, Hilton JF, Carroll PR (2011) The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117(22): 5039-5046. doi:10.1002/cncr.26169 Epub 2011 Jun 3
4. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR (2013) Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 31(11): 1428-1434
5. Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Moller H, Reuter V, Fearn P, Eastham J, Scardino P (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95(9): 1186-1194
6. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, Møller H, Scardino P, Warren JD, Park J, Younus A, Flake DD 2nd, Wagner S, Gutin A, Lanchbury JS, Stone S (2011) Transatlantic prostate group. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12(3): 245-255
7. Cuzick J, Berney DM, Fisher G, Mesher D, Møller H, Reid JE, Perry M, Park J, Younus A, Gutin A, Foster CS, Scardino P, Lanchbury JS, Stone S (2012) Transatlantic prostate group. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106(6): 1095-1099
8. Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S, Brewer D, Cooper CS, Clark J, Berney DM, Møller H, Scardino P, Sangale Z (2013) Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer. doi:10.1038/bjc.2013.248. (Epub ahead of print)
9. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB (2013) Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy. PLoS One Jun 24;8(6):e66855. doi:10.1371/journal.pone.0066855. Print 2013
10. Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Gutin A, Sangale Z, Lanchbury JS, Salama JK, Stone S (2013) Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys. Jun 4. [Epub ahead of print]
11. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90(10): 766-771
12. Markert EK, Mizuno H, Vazquez A, Levine AJ (2011) Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A 108(21276-21281): 9
13. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y et al (2011) mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 29: 2391-2396
14. Vasiljević N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, Mao X, Xue L, Yu Y, Shaw GL, Beltran L, Lu YJ, Berney DM, Cuzick J, Lorincz AT (2011) Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers 30(4): 151-161. doi:10.3233/DMA-2011-0790
15. Wang K, Peng HL, Li LK (2012) Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: a systematic review with meta-analysis. Asian Pac J Cancer Prev 13(11): 5665-5669
16. Wu CL, Schroeder BE, Ma XJ, Cutie CJ, Wu S, Salunga R, Zhang Y, Kattan MW, Schnabel CA, Erlander MG, McDougal WS (2013) Development and validation of a 32-gene prognostic index for prostate cancer progression. Proc Natl Acad Sci U S A 110(15): 6121-6126. doi:10. 1073/pnas.1215870110 Epub 2013 Mar 26